Compare CSTL & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | HELP |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.8M | 854.9M |
| IPO Year | 2019 | 2020 |
| Metric | CSTL | HELP |
|---|---|---|
| Price | $35.31 | $11.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $45.11 | $40.06 |
| AVG Volume (30 Days) | 254.6K | ★ 1.6M |
| Earning Date | 11-02-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $344,229,000.00 | N/A |
| Revenue This Year | $8.41 | N/A |
| Revenue Next Year | $10.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $17.72 | $3.76 |
| 52 Week High | $44.28 | $15.15 |
| Indicator | CSTL | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 63.06 | 49.77 |
| Support Level | $33.90 | $11.68 |
| Resistance Level | $36.85 | $14.75 |
| Average True Range (ATR) | 1.46 | 0.88 |
| MACD | -0.07 | -0.22 |
| Stochastic Oscillator | 86.78 | 11.44 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.